Studies have shown that the renal kallikrein-kinin system is involved in the regulation of body sodium and water excretion and arterial blood pressure. However, the mechanisms by which these actions occur have not been fully elucidated. Data obtained in preliminary studies suggest that the renal kallikrein-kinin system functions as a paracrine system, locally modulating renal function. The renal kallikrein-kinin system can stimulate production of both endothelium-derived relaxing factor (EDRF) and eicosanoids. The sites and regions where the renal kallikrein-kinin, EDRF and prostaglandin systems interact are not definitively established. Bradykinin can stimulate the release of both EDRF and prostacyclin from endothelial cells and prostaglandin E2 from renal tubular epithelial cells. Within the kidney, EDRF and eicosanoids may function in a cell-to-cell manner to regulate renal hemodynamic and excretory function. Furthermore, defects in these systems could lead to pathophysiologic states such as hypertension. The applicant has been involved in studies using an experimental model which functionally isolates the kidney in vivo in the conscious animal and can be employed for acute and chronic studies. Using this model, the applicant proposes to determine if the intrarenal kallikrein-kinin system is important physiologically in the control of renal function through modulation of EDRF and/or eicosanoid release. Specifically, the applicant proposes to localize the cellular targets of intrarenal kallikrein-kinin system by monitoring the levels of second messengers for EDRF (cyclic GMP) and eicosanoids (cyclic AMP) following receptor stimulation. The intrarenal paracrine effects of the kallikrein-kinin system will be explored with the use of a novel method developed by the applicant for interstitial fluid sampling in vivo in conscious animals. The proposed studies are related to the long term goal of increased understanding of the pathophysiology of fluid/electrolyte disorders and hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL047669-02
Application #
3366904
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
1992-07-07
Project End
1995-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
Schools of Medicine
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Siragy, Helmy M; Awad, Alaa; Abadir, Peter et al. (2003) The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology 144:2229-33
Millatt, Lesley J; Whitley, Guy StJ; Li, Dechun et al. (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108:1493-8
Siragy, Helmy M; El-Kersh, Mohamed A; De Gasparo, Marc et al. (2002) Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP. J Hypertens 20:1157-63
Siragy, H M; de Gasparo, M; El-Kersh, M et al. (2001) Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38:183-6
Millatt, L J; Siragy, H M (2000) Renal cyclic 3',5'-guanosine monophosphate and sodium excretion in Dahl salt-resistant and Dahl salt-sensitive rats: comparison of the roles of bradykinin and nitric oxide. J Hypertens 18:1491-6
Millatt, L J; Siragy, H M (2000) Age-related changes in renal cyclic nucleotides and eicosanoids in response to sodium intake. Hypertension 35:643-7
Siragy, H M; de Gasparo, M; Carey, R M (2000) Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 35:1074-7
Siragy, H M; Bedigian, M (1999) Mechanism of action of angiotensin-receptor blocking agents. Curr Hypertens Rep 1:289-95
Siragy, H M; Senbonmatsu, T; Ichiki, T et al. (1999) Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 104:181-8
Siragy, H M; Carey, R M (1999) Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33:1237-42

Showing the most recent 10 out of 21 publications